Related Experiment Video

Updated: Jun 21, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

PDK3 drives colorectal carcinogenesis and immune evasion and is a therapeutic target for boosting immunotherapy

Zhiqiang Liu1, Liang Li2, Lei Liu3

  • 1Department of Neurology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College Nanchang 330006, Jiangxi, China.

American Journal of Cancer Research
|July 15, 2024
PubMed

Insights

Pyruvate Dehydrogenase Kinase 3 (PDK3) fuels colon cancer by activating PI3K-AKT signaling and PD-L1 expression, while suppressing CD8+ T cell immunity. Inhibiting PDK3 enhances anti-tumor T cell responses and improves treatment outcomes.

Area of Science:

  • Oncology
  • Cancer Immunology
  • Molecular Biology

Background:

  • Pyruvate Dehydrogenase Kinase 3 (PDK3) is implicated in various cancers, but its role in colon cancer and its interaction with the immune microenvironment are not fully understood.
  • Understanding PDK3's function is crucial for developing targeted therapies in colorectal cancer.

Purpose of the Study:

  • To investigate the role of PDK3 in colon cancer proliferation, immune evasion, and its potential as a therapeutic target.
  • To explore the combined efficacy of PDK3 inhibition and PD-1 blockade in preclinical colon cancer models.

Main Methods:

  • Pan-cancer analysis of TCGA data to assess PDK3 expression and immune microenvironment composition.
  • In vitro studies on colon cancer cells to examine PDK3's effect on signaling pathways and immune markers.
  • In vivo experiments using murine tumor models to evaluate the therapeutic potential of PDK3 inhibition alone and in combination with PD-1 blockade.

Main Results:

  • PDK3 is highly expressed in colorectal cancer, promoting proliferation via PI3K-AKT signaling and inhibiting anti-tumor immunity by suppressing antigen presentation and CD8+ T cell infiltration.
  • PDK3 facilitates STAT1 activation and upregulates PD-L1 expression in colon cancer cells.
  • Inhibition of PDK3 enhances CD8+ T cell-mediated cytotoxicity and, when combined with PD-1 blockade, significantly suppresses tumor growth and improves survival in murine models.

Conclusions:

  • PDK3 plays a critical role in colon cancer progression by modulating oncogenic signaling pathways and immune evasion mechanisms.
  • Targeting PDK3, particularly in combination with immune checkpoint inhibitors like anti-PD-1, represents a promising therapeutic strategy for colon cancer.
Keywords:
Colorectal cancerPyruvate Dehydrogenase Kinase 3immune infiltration

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.0K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K